Rapid endotheliitis and vascular damage characterize SARS-CoV-2 infection in a human lung-on-chip model
Open accessPublished version of a preprint
The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
Severe cases of SARS-CoV-2 infection are characterized by hypercoagulopathies and systemic endotheliitis of the lung microvasculature. The dynamics of vascular damage, and whether it is a direct consequence of endothelial infection or an indirect consequence of an immune cell-mediated cytokine storm remain unknown. Using a vascularized lung-on-chip model, we find that infection of alveolar epithelial cells leads to limited apical release of virions, consistent with reports of monoculture infection. However, viral RNA and proteins are rapidly detected in underlying endothelial cells, which are themselves refractory to apical infection in monocultures. Although endothelial infection is unproductive, it leads to the formation of cell clusters with low CD31 expression, a progressive loss of barrier integrity and a pro-coagulatory microenvironment. Viral RNA persists in individual cells generating an inflammatory response, which is transient in epithelial cells but persistent in endothelial cells and typified by IL-6 secretion even in the absence of immune cells. Inhibition of IL-6 signalling with tocilizumab reduces but does not prevent loss of barrier integrity. SARS-CoV-2-mediated endothelial cell damage thus occurs independently of cytokine storm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · cited 1×
“On the other hand, infection resulted in increased expression of the TMPRSS2 protease (Hoffmann et al, 2020) required to cleave the spike protein for viral entry at 1 dpi in both cell types relative to uninfected controls (Fig 1F and I), with variable expression levels across chips.”
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015432 · Cited by 5,613 · cited 2×
“Autopsy reports show numerous microvascular thrombi in the lungs of deceased patients together with evidence of the intracellular presence of the virus in vascular cells (Ackermann et al, 2020; Carsana et al, 2020).”
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046 · cited 10×
“No IL-6 was detected in the vascular effluent from uninfected controls.”
InfluentialReconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250 · cited 1×
“The epithelial face was incubated with epithelial base medium with 1 µ M dexamethasone (Sigma-Aldrich) without FBS supplementation to promote tight junction formation and surfactant expression as reported in previous lung-on-chip studies(Huh et al, 2010; Hassell et al, 2017).”
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222 · cited 5×
“Similarly, most infections of alveolar epithelial cells are usually performed at high MOI (Blanco-Melo et al, 2020).”
InfluentialBhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305 · cited 1×
“Organ-on-chip technologies recreate key aspects of human physiology in a bottom-up and modular manner (Bhatia & Ingber, 2014).”
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984 · cited 1×
“We observed that low levels of intracellular viral RNA generate an NF-KB-mediated pro-inflammatory response, with suppression of antiviral interferon responses, consistent with reports of the effect of a number of viral proteins (Hadjadj et al, 2020; Thoms et al, 2020).”
The Architecture of SARS-CoV-2 Transcriptome
Kim, D., Lee, J.-Y., Yang, J.-S., Kim, J. W., Kim, V. N., & Chang, H. (2020) · Cell · doi:10.1016/j.cell.2020.04.011 · Cited by 2,123 · cited 1×
“…in replication kinetics can also be appreciated from the fact that whereas the N gene is most abundant during productive infection in Vero E6 cells (Kim et al, 2020), The detection of SARS-CoV-2 genomes in the endothelial layer within 1 dpi suggests rapid dissemination through basolateral transfer…”
Monteil, V., Kwon, H., Prado, P., Hagelkrüys, A., Wimmer, R. A., Stahl, M., Leopoldi, A., Garreta, E., Hurtado del Pozo, C., Prosper, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.004 · Cited by 2,122 · cited 4×
“Notably, NRP1 is likely to be located along the basal surface of the endothelial cells as an integrin-binding protein (Valdembri et al, 2009), and SARS-CoV-2 has been shown to infect vascularized organoids, albeit at high MOI (Monteil et al, 2020).”
InfluentialNeuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity
Cantuti-Castelvetri, L., Ojha, R., Pedro, L. D., Djannatian, M., Franz, J., Kuivanen, S., van der Meer, F., Kallio, K., Kaya, T., Anastasina, M., et al. (2020) · Science · doi:10.1126/science.abd2985 · Cited by 1,925 · cited 1×
“Neuropilin-1 (NRP1), an integrin-binding protein (Valdembri et al, 2009), has recently been reported to be an alternative receptor for SARS-CoV-2 entry (Cantuti-Castelvetri et al, 2020; Daly et al, 2020) that is highly expressed in pulmonary microvascular cells.”
Cited by
The cGAS–STING pathway drives type I IFN immunopathology in COVID-19
Domizio, J. D., Gulen, M. F., Saidoune, F., Thacker, V. V., Yatim, A., Sharma, K., Nass, T., Guenova, E., Schaller, M., Conrad, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04421-w · Cited by 538
Self-citationImmunomodulation by endothelial cells — partnering up with the immune system?
Amersfoort, J., Eelen, G., & Carmeliet, P. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00694-4 · Cited by 525
Human disease models in drug development
Loewa, A., Feng, J. J., & Hedtrich, S. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00063-3 · Cited by 331
Mucosal immune responses to infection and vaccination in the respiratory tract
Mettelman, R. C., Allen, E. K., & Thomas, P. G. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.013 · Cited by 271
“…infection of ECs by SARS-CoV-2; however, interaction with the virus lead to EC clustering, reduced CD31 expression, loss of barrier integrity, and production of pro-coagulation factors (Thacker et al., 2021), signs of severe disease that may be enhanced in aged individuals (Angelidis et al., 2019).”
Organ-on-a-chip meets artificial intelligence in drug evaluation
Deng, S., Li, C., Cao, J., Cui, Z., Du, J., Fu, Z., Yang, H., & Chen, P. (2023) · Theranostics · doi:10.7150/thno.87266 · Cited by 260
“matory response and loss of barrier integrity, the latter can be alleviated by tocilizumab treatment [255].”
BackgroundMethodSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection
Synowiec, A., Szczepański, A., Barreto-Duran, E., Lie, L. K., & Pyrc, K. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00133-20 · Cited by 212
Organs-on-chips technologies – A guide from disease models to opportunities for drug development
Monteduro, A. G., Rizzato, S., Caragnano, G., Trapani, A., Giannelli, G., & Maruccio, G. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115271 · Cited by 175
Human organoid models to study SARS-CoV-2 infection
Han, Y., Yang, L., Lacko, L. A., & Chen, S. (2022) · Nature Methods · doi:10.1038/s41592-022-01453-y · Cited by 164
Sharma, K., Dhar, N., Thacker, V. V., Simonet, T. M., Signorino‐Gelo, F., Knott, G. W., & McKinney, J. D. (2021) · eLife · doi:10.7554/elife.66481 · Cited by 130
Self-citationCOVID-19 and the Vasculature: Current Aspects and Long-Term Consequences
Martínez-Salazar, B., Holwerda, M., Stüdle, C., Piragyte, I., Mercader, N., Engelhardt, B., Rieben, R., & Döring, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.824851 · Cited by 114
Liu, S., Kumari, S., He, H., Mishra, P., Singh, B. N., Singh, D., Liu, S., Srivastava, P., & Li, C. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115285 · Cited by 112
Wang, P., Jin, L., Zhang, M., Wu, Y., Duan, Z., Guo, Y., Wang, C., Guo, Y., Chen, W., Liao, Z., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01054-w · Cited by 126
From Organ-on-a-Chip to Human-on-a-Chip: A Review of Research Progress and Latest Applications
Huang, Y., Liu, T., Huang, Q., & Wang, Y. (2024) · ACS Sensors · doi:10.1021/acssensors.4c00004 · Cited by 110
Organ-on-chip models for infectious disease research
Alonso‐Román, R., Mosig, A. S., Figge, M. T., Papenfort, K., Eggeling, C., Schacher, F. H., Hube, B., & Gresnigt, M. S. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01645-6 · Cited by 101
WIRTH, K. J., Scheibenbogen, C., & Paul, F. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03143-3 · Cited by 82
“Endothelial dysfunction, which is clearly present in ME/CFS and PCS, has been found associated with cognitive impairment in different conditions, in the elderly as well as in children [13, 37].”
BackgroundInfluentialMycobacteria–host interactions in human bronchiolar airway organoids
Iakobachvili, N., Leon‐Icaza, S. A., Knoops, K., Sachs, N., Mazères, S., Siméone, R., Peixoto, A., Bernard, C., Murris‐Espin, M., Mazières, J., et al. (2021) · Molecular Microbiology · doi:10.1111/mmi.14824 · Cited by 87
The potential role of neopterin in Covid-19: a new perspective
Al-Kuraishy, H. M., Al-Gareeb, A. I., Alzahrani, K. J., Martins, N. A., & Batiha, G. E. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04232-z · Cited by 81
Long-term Lung Abnormalities Associated with COVID-19 Pneumonia
Kanne, J. P., Little, B. P., Schulte, J. J., Haramati, A., & Haramati, L. B. (2022) · Radiology · doi:10.1148/radiol.221806 · Cited by 90
“The current consensus favors endotheliitis (56,65,66) and extension of the pulmonary inflammatory process (67) rather than vasculitis as the dominant explanation for the wide-ranging COVID-19– associated pulmonary vascular abnormalities.”
Montezano, A. C. I., Camargo, L. L., Mary, S., Neves, K. B., Rios, F. J. O., Stein, R., Alves-Lopes, R., Beattie, W., Thomson, J., Herder, V., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41115-3 · Cited by 75
“Tissue damage commonly observed in COVID-19 is due to activation of immune pathways, affecting vascular cells such as endothelial cells and leading to loss of integrity, vascular dysfunction, and inflammation 17–21 .”
BackgroundComparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
Tamura, T., Yamasoba, D., Oda, Y., Ito, J., Kamasaki, T., Nao, N., Hashimoto, R., Fujioka, Y., Suzuki, R., Wang, L., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05081-w · Cited by 64
“Airway/lung-on-a-chips are known to be useful tools for analyzing the behavior of pathogens including SARS-CoV-2 17 – 19 .”
Jung, O., Tung, Y., Sim, E., Chen, Y.-C., Lee, E. M., Ferrer, M., & Song, M. J. (2022) · Biofabrication · doi:10.1088/1758-5090/ac32a5 · Cited by 65
Sengupta, A., Roldán, N., Kiener, M., Froment, L., Raggi, G., Imler, T., Maddalena, L. L. D., Rapet, A., May, T., Carius, P., et al. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2022.840606 · Cited by 62
“, 2020), or lung microvascular endothelial cells (Thacker et al., 2021).”
BackgroundModelling host–microbiome interactions in organ-on-a-chip platforms
Shin, Y. C., Than, N., Min, S., Shin, W., & Kim, H. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00130-9 · Cited by 65
“…interface can be engineered by integrating a patient-derived organoid epithelium and primary vascular endothelium, to investigate in vivo-relevant SARS-CoV-2 viral pathogenesis, such as lung injury, vascular dysfunction and localized inflammatory responses (for example, endotheliitis 128 ).”
Mechanopathology of biofilm-like Mycobacterium tuberculosis cords
Mishra, R., Hannebelle, M. T. M., Patil, V. P., Dubois, A., García-Mouton, C., Kirsch, G. M., Jan, M., Sharma, K., Guex, N., Sordet‐Dessimoz, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.09.016 · Cited by 61
Self-citationIn vitro immunity: an overview of immunocompetent organ-on-chip models
Morrison, A. I., Sjoerds, M. J., Vonk, L. A., Gibbs, S., & Koning, J. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1373186 · Cited by 61
“Furthermore, a severe immune overreaction, known as a cytokine storm, was modelled when SARS-CoV-2 infected patient samples were tested on a lung-on-chip, where the high cytokine levels were suppressed after monoclonal antibody treatment (37).”
BackgroundKiener, M., Roldán, N., Machahua, C., Sengupta, A., Geiser, T., Guenat, O. T., Funke-Chambour, M., Hobi, N., & Julio, M. K. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.644678 · Cited by 55
Connecting the Dots: Interplay of Pathogenic Mechanisms between COVID-19 Disease and Mucormycosis
Prakash, H., Skiada, A., Paul, R. A., Chakrabarti, A., & Rudramurthy, S. M. (2021) · Journal of Fungi · doi:10.3390/jof7080616 · Cited by 56
“Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to the Angiotensin-Converting Enz me 2 (ACE2) receptor on endothelial cells, followed by the internalisation of viral particles leading to coagulation, ndotheliitis and endotheli l cell death [33,34].”
BackgroundNeurological complications associated with Covid‐19; molecular mechanisms and therapeutic approaches
Mehrabani, M. M., Karvandi, M. S., Maafi, P., & Doroudian, M. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2334 · Cited by 58
“factor pathway inhibitor (TFPI)) and ‘thrombomodulin’ (THBD), two anticoagulatory factors, in virus‐infected ECs.(171,172) Other studies have suggested the impairment of thrombin generation control”
BackgroundInfluentialHuman Organoids and Organs‐on‐Chips for Addressing COVID‐19 Challenges
Wang, Y., Wang, P., & Qin, J. (2022) · Advanced Science · doi:10.1002/advs.202105187 · Cited by 51
Organoids‐On‐a‐Chip for Personalized Precision Medicine
Man, Y., Liu, Y., Chen, Q., Zhang, Z., Li, M., Xu, L., Tan, Y., & Liu, Z. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401843 · Cited by 58
Xiong, S., Zhang, L., Qadir, A. S., Richner, J. M., Class, J., Rehman, J., & Malik, A. B. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316925 · Cited by 51
Organ-on-chip systems as a model for nanomedicine
Stavrou, M., Phung, N. B., Grimm, J., & Andreou, C. (2023) · Nanoscale · doi:10.1039/d3nr01661g · Cited by 51
In Vitro Lung Models and Their Application to Study SARS-CoV-2 Pathogenesis and Disease
Heinen, N., Klöhn, M., Steinmann, E., & Pfaender, S. (2021) · Viruses · doi:10.3390/v13050792 · Cited by 47
Organoid and microfluidics-based platforms for drug screening in COVID-19
Ramezankhani, R., Solhi, R., Chai, Y. C., Vosough, M., & Verfaillie, C. M. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.12.014 · Cited by 47
Application of microfluidic technologies on COVID-19 diagnosis and drug discovery
Lin, Z., Zou, Z., Pu, Z., Wu, M., & Zhang, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.014 · Cited by 46
What Can an Organ-on-a-Chip Teach Us About Human Lung Pathophysiology?
Bai, H., & Ingber, D. E. (2022) · Physiology · doi:10.1152/physiol.00012.2022 · Cited by 42
Organs-on-Chips Platforms Are Everywhere: A Zoom on Biomedical Investigation
Zommiti, M., Connil, N., Tahrioui, A., Groboillot, A., Barbey, C., Konto‐Ghiorghi, Y., Lesouhaitier, O., Chevalier, S., & Feuilloley, M. G. J. (2022) · Bioengineering · doi:10.3390/bioengineering9110646 · Cited by 47
Biomimetic lung-on-a-chip to model virus infection and drug evaluation
Tan, J., Guo, Q., Tian, L., Pei, Z., Li, D., Wu, M., Zhang, J., & Gao, X. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106329 · Cited by 45
Immune cell extravasation in an organ-on-chip to model lung inflammation
van Os, L., Yeoh, W. J., Witz, G., Ferrari, D., Krebs, P., Chandorkar, Y., Zeinali, S., Sengupta, A., & Guenat, O. T. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106485 · Cited by 45
“, 2010), or to assess SARSCOV2 infection-related damage (Thacker et al., 2021; Zhang et al., 2021) and consist of two compartments, an endothelial and an epithelial channel separated by a porous”
BackgroundAn immune-competent lung-on-a-chip for modelling the human severe influenza infection response
Ringquist, R., Bhatia, E., Chatterjee, P., Maniar, D., Fang, Z., Franz, P., Kramer, L., Ghoshal, D., Sonthi, N., Downey, E., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01491-9 · Cited by 60
Zarkoob, H., Allué‐Guardia, A., Chen, Y., Garcia‐Vilanova, A., Jung, O., Coon, S. L., Song, M. J., Park, J., Oladunni, F. S., Miller, J., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03753-7 · Cited by 40
COVID-19 Coagulopathy: From Pathogenesis to Treatment
Alnima, T., Mulder, M. M. G., van Bussel, B. C. T., & Cate, H. T. (2022) · Acta Haematologica · doi:10.1159/000522498 · Cited by 38
Advances of microfluidic lung chips for assessing atmospheric pollutants exposure
Wang, H., Yin, F., Li, Z., Su, W., & Li, D. (2023) · Environment International · doi:10.1016/j.envint.2023.107801 · Cited by 43
Development of lung tissue models and their applications
Petpiroon, N., Netkueakul, W., Sukrak, K., Wang, C., Liang, Y. T., Wang, M., Liu, Y., Li, Q., Kamran, R., Naruse, K., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122208 · Cited by 44
Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study
Bruno, R. M., Badhwar, S., Abid, L., Agharazii, M., Anastasio, F., Bellien, J., Burghuber, O., Faconti, L., Filipovský, J., Ghiadoni, L., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf430 · Cited by 39
“Viral RNA persists in endothelial cells, generating a persistent inflammatory response, even in the absence of immune cells, 27 thus constituting a molecular basis for development of vascular damage.”
Imaging 3D cell cultures with optical microscopy
Hsieh, H.-C., Han, Q., Brenes, D., Bishop, K. W., Wang, R., Wang, Y., Poudel, C., Glaser, A. K., Freedman, B., Vaughan, J. C., et al. (2025) · Nature Methods · doi:10.1038/s41592-025-02647-w · Cited by 51
“Confocal microscopy has often been used to quantify such relationships 122,125,126,128–131 .”
Shiraki, K., Sato, N., Sakai, K., Matsumoto, S., Kaszynski, R. H., & Takemoto, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108121 · Cited by 35
“Direct inhibition of SARS-CoV-2 replication in endothelial cells prevents microangiopathy in the nervous, cardiovascular, and pulmonary systems (Ackermann et al., 2020; Aid et al., 2020; Bhatnagar et al., 2021; S. X. Gu et al., 2021; Thacker et al., 2021).”
BackgroundŽarković, N., Jakovčević, A., Mataić, A., Jaganjac, M., Vuković, T., Waeg, G., & Žarković, K. (2022) · Cells · doi:10.3390/cells11030444 · Cited by 29
Chu, J. T. S., & Lamers, M. M. (2024) · npj Viruses · doi:10.1038/s44298-024-00017-5 · Cited by 37
“Since the fi rst development of a lung alveolus organ chip, numerous designs have become available at pre-commercial and commercial stages, allowing for prototyping of cellular, tissue, and organ level responses for different viral diseases 122 – 125 .”
Organoids as models of immune-organ interaction
Harter, M. F., Recaldin, T., & Gjorevski, N. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116214 · Cited by 36
Nizamoglu, M., Joglekar, M. M., Almeida, C. R., Larsson‐Callerfelt, A., Dupin, I., Guenat, O. T., Henrot, P., van Os, L., Otero, J., Elowsson, L., et al. (2023) · European Respiratory Review · doi:10.1183/16000617.0042-2023 · Cited by 40
Fisher, C. R., Medie, F. M., Luu, R. J., Gaibler, R. B., Mulhern, T. J., Miller, C. R., Zhang, C. J., Rubio, L. D., Marr, E. E., Vijayakumar, V., et al. (2023) · Cells · doi:10.3390/cells12222639 · Cited by 28
“Finally, work combining primary cells and wild-type virus in an organ-on-chip format has exhibited viral replication too low for rigorous drug development [23,24].”
Method3D Lung Tissue Models for Studies on SARS-CoV-2 Pathophysiology and Therapeutics
Plebani, R., Bai, H., Si, L., Li, J., Zhang, C., & Romano, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710071 · Cited by 25
“[81] used the Lung-on-a-Chip model to study SARS-CoV-2 infection and its effects on endothelial cells (EC).”
MethodTailoring biomaterials for biomimetic organs-on-chips
Sun, L., Bian, F., Xu, D., Luo, Y., Wang, Y., & Zhao, Y. (2023) · Materials Horizons · doi:10.1039/d3mh00755c · Cited by 27
van Doorn, P., Rosing, J., Duckers, C., Hackeng, T. M., Simioni, P., & Castoldi, E. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656549 · Cited by 25
Endothelial inflammation and dysfunction in COVID-19
Sbirkov, Y., Dzharov, V., Todorova, K. O., Hayrabedyan, S., & Sarafian, V. S. (2022) · VASA · doi:10.1024/0301-1526/a000991 · Cited by 23
Ruggiero, V., Aquino, R. P., Gaudio, P. D., Campiglia, P., & Russo, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061135 · Cited by 59
3D-printed airway model as a platform for SARS-CoV-2 infection and antiviral drug testing
Lee, Y., Lee, M. K., Lee, H., Kim, B., Kim, M., & Jung, S. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122689 · Cited by 24
Integration of nanobiosensors into organ-on-chip systems for monitoring viral infections
Zhang, J., Kim, M., Lee, S., & Park, S. (2024) · Nano Convergence · doi:10.1186/s40580-024-00455-0 · Cited by 19
“[87] Two channels separated by a porous membrane pHAECs, pHLECs SARS-CoV-2 - cGAS–STING Pathway drives type I IFN immunopathology in COVID-19.”
An Insight on Microfluidic Organ-on-a-Chip Models for PM2.5-Induced Pulmonary Complications
Shah, D., Dave, B. P., Chorawala, M. R., Prajapati, B. G., Singh, S. K., Elossaily, G. M., Ansari, M. N., & Ali, N. (2024) · ACS Omega · doi:10.1021/acsomega.3c10271 · Cited by 22
Analytical and biomedical applications of microfluidics in traditional Chinese medicine research
Shen, P., Jia, Y., Shi, S., Sun, J. T., & Han, X. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116851 · Cited by 18
Vascular microphysiological systems (MPS): biologically relevant and potent models
Breuil, L., Kitada, A., Yadav, S., Zhou, H., Fujimoto, K., & Yokokawa, R. (2025) · Lab on a Chip · doi:10.1039/d5lc00014a · Cited by 19
Yadav, S., Fujimoto, K., Takenaga, T., Takahashi, S., Muramoto, Y., Mikawa, R., Noda, T., Gotoh, S., & Yokokawa, R. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01444-2 · Cited by 28
“Co-culturing endothelial cells further enhanced the resemblance to the in vivo interface of human airways and alveoli, as noted in previous MPS studies 29–32 .”
Organ-on-a-chip models for elucidating the cellular biology of infectious diseases
Yokoi, F., Deguchi, S., & Takayama, K. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119504 · Cited by 21
Human models for COVID‐19 research
Woodall, M. N. J., Masonou, T., Case, K., & Smith, C. M. (2021) · The Journal of Physiology · doi:10.1113/jp281499 · Cited by 13
“2021) and wild-type SARS-CoV-2 virus (Thacker et al. 2021; Deinhardt-Emmer et al. 2021).”
BackgroundAirway and Alveoli Organoids as Valuable Research Tools in COVID-19
de Oliveira, M., Síbio, M. T. D., da Costa, F. A. D. S., & Sakalem, M. E. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00306 · Cited by 14
Bordoni, V., Mariotti, D., Matusali, G., Colavita, F., Cimini, E., Ippolito, G., & Agrati, C. (2022) · Cells · doi:10.3390/cells11182912 · Cited by 14
“Although there is evidence of SARS-CoV-2 affecting in vivo the vascular endothelium, in vitro data on the mechanisms involved in such events are limited [1,15,22].”
BackgroundElucidation of the liver pathophysiology of COVID-19 patients using liver-on-a-chips
Deguchi, S., Kosugi, K., Hashimoto, R., Sakamoto, A., Yamamoto, M., Krol, R. P., Gee, P., Negoro, R., Noda, T., Yamamoto, T., et al. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad029 · Cited by 15
“Such endothelial barrier disruption was also reported in SARS-CoV-2-infected airway, lung-and gut-on-a-chip (9, 16, 17).”
Advancements in organs-on-chips technology for viral disease and anti-viral research
Li, J., Bai, H., Wang, Z., Beibei, X., Olson, K. N. P., Liu, C., Su, Y., Hao, J., Shen, J., Xi, X., et al. (2023) · Organs-on-a-Chip · doi:10.1016/j.ooc.2023.100030 · Cited by 13
Koceva, H., Amiratashani, M., Akbarimoghaddam, P., Hoffmann, B., Zhurgenbayeva, G., Gresnigt, M. S., Marcelino, V. R., Eggeling, C., Figge, M. T., Amorim, M. J., et al. (2025) · Open Biology · doi:10.1098/rsob.240231 · Cited by 16
“Finaly, SARS-CoV-2 infection studies in lung-on-chip revealed rapid endothelial cell impact, with IL-6 elevation indicating a direct viral effect and identifying the cGAS-STING pathway as a key inducer of cell death and a potential therapeutic target [176].”
Zhou, Y., Qiao, H., Xu, F., Zhao, W., Wang, J., Gu, L., Chen, P., & Peng, M. (2023) · Lab on a Chip · doi:10.1039/d3lc00131h · Cited by 12
Microfluidic strategies for biomimetic lung chip establishment and SARS-CoV2 study
Wang, H., Wen, T., Zhu, W., Li, K., Gong, X., & Li, Z. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100905 · Cited by 18
“Thacker et al. [110] analyzed human lung chips with vertical designs and found that infective particles were limited to the epithelial channel (Fig.”
BackgroundInfluentialFujimoto, K., Kameda, Y., Nagano, Y., Deguchi, S., Yamamoto, T., Krol, R. P., Gee, P., Matsumura, Y., Okamoto, T., Nagao, M., et al. (2024) · Lab on a Chip · doi:10.1039/d3lc00768e · Cited by 13
Organoids in respiratory virus research: advances and perspectives
Li, X., Xiao, H., Zhou, M., Yang, C., Yang, X., Cheng, T., Yuan, L., & Xia, N. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00343-x · Cited by 11
“In an alveolar cell microarray with SARS-CoV-2 infection, tocilizumab was shown to mitigate barrier damage, which was accomplished by suppressing the inflammatory response rather than controlling viral replication [205].”
Daum, S., Decristoforo, L., Mousa, M., Salcher, S., Plattner, C., Hosseinkhani, B., Trajanoski, Z., Wolf, D. G. F., Carmeliet, P., & Pircher, A. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02221-6 · Cited by 14
“ECs were shown to be directly but unproductively infected by SARS-CoV-2, yet their over-activated immune response during acute COVID-19 promotes pathogenesis by upregulating ICAM-1 and pro-inflammatory cytokines while losing barrier integrity due to reduced CD31 expression [153, 154].”
Harnessing the power of microphysiological systems for COVID-19 research
Kleinstreuer, N., & Holmes, A. M. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.06.020 · Cited by 12
Modelling SARS-CoV-2 infection in a human alveolus microphysiological system
Šuligoj, T., Coombes, N. S., Booth, C., Savva, G. M., Bewley, K. R., Funnell, S. G. P., & Juge, N. (2024) · Access Microbiology · doi:10.1099/acmi.0.000814.v3 · Cited by 10
Luk, C. H., Conway, G. L., Goh, K. J., Fearns, A., Hernández, I. R., Day, N. J., Athanasiadi, N., D’Antuono, R., Pellegrino, E., Stucki, J. D., et al. (2026) · Science Advances · doi:10.1126/sciadv.aea9874 · Cited by 16
A proof-of-concept study poised to remodel the drug development process
Nahle, Z. A. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2022.1053588 · Cited by 12
Lessons from SARS‑CoV‑2 and its variants (Review)
Qin, Z., Sun, Y., Zhang, J., Zhou, L., Chen, Y., & Huang, C. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12779 · Cited by 11
“Massive viral duplication in the lung triggers the immune response, which causes aggregation and accumulation of inflammatory cells, resulting in typical symptoms of viral pneumonia (10).”
BackgroundWeener, H. J., van Haaps, T. F., van Helden, R. W. J., Albers, H. J., Haverkate, R., Middelkamp, H. H. T., Ridderikhof, M. L., van Mens, T. E., van den Berg, A., Mummery, C. L., et al. (2025) · Lab on a Chip · doi:10.1039/d4lc00848k · Cited by 13
Bisconti, F., Abreu, H., Nguyen, T. D., Stolfi, F., Corbezzolo, N., Gigli, G., Raineri, D., Cappellano, G., Polini, A., Gervaso, F., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1712796 · Cited by 10
Butyrate Protects against SARS-CoV-2-Induced Tissue Damage in Golden Hamsters
Yu, H., Yuan, L., Yan, Z., Zhou, M., Ye, J., Wu, K., Chen, W.-J., Chen, R., Xia, N., Guan, Y., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814191 · Cited by 11
“In a SARS-CoV-2-infected 225 vascularized lung-on-chip model, despite unproductive viral replication, lower 226 CD31 expression and decreased barrier integrity were observed (33).”
In vitro high-content tissue models to address precision medicine challenges
Afewerki, S., Stocco, T. D., Silva, A. D. R., Furtado, A. S. A., de Sousa, G. F., Ruiz‐Esparza, G. U., Webster, T. J., Marciano, F. R., Strømme, M., Zhang, Y. S., et al. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101108 · Cited by 9
Multi-organ microphysiological system: A new paradigm for COVID-19 research
Wang, P., Wang, Y., & Qin, J. (2023) · Organs-on-a-Chip · doi:10.1016/j.ooc.2023.100029 · Cited by 12
Vascular dysfunction in hemorrhagic viral fevers: opportunities for organotypic modeling
Zarate-Sanchez, E., George, S. C., Moya, M. L., & Robertson, C. (2024) · Biofabrication · doi:10.1088/1758-5090/ad4c0b · Cited by 9
Fabrication of sac-like hydrogel membranes for replicating curved tissue barriers on chips
She, W., Shen, C., Ying, Y., & Meng, Q. (2023) · Lab on a Chip · doi:10.1039/d3lc00807j · Cited by 7
Organoids and microphysiological systems for pharmaceutical research of viral respiratory infections
Deguchi, S., Yokoi, F., & Takayama, K. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101041 · Cited by 8
Zhang, Y., Yang, J., Liu, P., Zhang, R., Li, J.-D., Bi, Y., & Li, Y. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106509 · Cited by 7
Pathophysiological Aspects of COVID-19-Associated Vasculopathic Diseases
Greistorfer, T., & Jud, P. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0043-1768969 · Cited by 7
Quezada, L. A. L., Medie, F. M., Luu, R. J., Gaibler, R. B., Gabriel, E. P., Rubio, L. D., Mulhern, T. J., Marr, E. E., Borenstein, J. T., Fisher, C. R., et al. (2024) · Advanced Biology · doi:10.1002/adbi.202300511 · Cited by 12
Airway models in a pandemic: Suitability of models in modeling SARS-CoV-2
Teo, A., Chua, C. L. L., & Chan, L. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010432 · Cited by 6
“Similarly, vascularized lungon-a-chip model has revealed SARS-CoV-2 infection in endothelial cells, causing disruption of barrier integrity and promoting a pro-coagulatory microenvironment [47].”
BackgroundMultilayered microfluidic platform for three-dimensional vascularized organ-on-a-chip applications
Zhou, C., Li, Z., Xu, J., Yu, D., Xuan, L., & Wang, X. (2025) · Bio-Design and Manufacturing · doi:10.1631/bdm.2500091 · Cited by 6
Wu, T., Rabi, S. A., Michaud, W. A., Becerra, D. C., Gilpin, S. E., Mino-Kenudson, M. A., & Ott, H. C. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121509 · Cited by 5
“Recently, several groups reported the application of human lung cells [3, 4], organoids [5-8], and organ-on-a-chip microfluidic systems [9-13] for the study of SARS-CoV-2 infection and induced immune responses.”
Lipnitsky, A., Polovets, N. V., Surkova, R. S., MURUGOVA, A. A., Toporkov, A. V., & Viktorov, D. V. (2021) · Immunopathology Allergology Infectology · doi:10.14427/jipai.2021.4.65 · Cited by 6
SARS-CoV-2 causes human BBB injury and neuroinflammation indirectly in a linked organ chip platformPreprint
Wang, P., Jin, L., Zhang, M., Wu, Y., Duan, Z., Chen, W., Wang, C., Liao, Z., Han, J.-B., Guo, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.05.463205 · Cited by 5
Mansouri, M., Ahmed, A., Ahmad, S. D., McCloskey, M. C., Joshi, I. M., Gaborski, T. R., Waugh, R. E., McGrath, J. L., Day, S. W., & Abhyankar, V. V. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.28.486107 · Cited by 5
Unravelling approaches to study macrophages: from classical to novel biophysical methodologies
Vishnyakova, P., Elchaninov, A. V., Fatkhudinov, T., & Kolesov, D. V. (2025) · PeerJ · doi:10.7717/peerj.19039 · Cited by 4
“Lung-on-a-chip models with incorporated murine macrophages were used to study in fl ammatory processes of viral or bacterial nature in the lungs ( Thacker et al., 2021 , 2020 ).”
Micro-physiological system of human lung: The current status and application to drug discovery
Sone, N., & Gotoh, S. (2025) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101050 · Cited by 6
Sheng, H., Liang, Y., Lauschke, V. M., & Wang, Y. (2025) · Engineering · doi:10.1016/j.eng.2025.01.019 · Cited by 6
Metadata
- Authors
- Thacker, V. V., Sharma, K., Dhar, N., Mancini, G.-F., Sordet-Dessimoz, J., & McKinney, J. D.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Corresponding author
- Thacker, Vivek V
- Sharma, Kunal
- Dhar, Neeraj
- Venue
- The EMBO Reports
- Published
- 2021-05-27
- Volume
- 22
- Issue
- 6
- Pages
- e52744-e52744
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- PMC
- PMC8183417
- OpenAlex
- W3159931117
- Cited by
- 142
- References
- 81
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 17 · 2023: 30 · 2022: 36 · 2021: 16
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- EMBO Reports (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- Novartis Foundation for Medical-Biological Research ((#20C240))
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030B_176397)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Keywords
- SARS-CoV-2, endothelial inflammation, vascular injury, lung-on-a-chip, endothelial cell infection, alveolar epithelial cells, hypercoagulability, interleukin-6, tocilizumab, endothelial barrier integrity, viral RNA persistence, cytokine storm, COVID-19 pandemic
- MeSH terms
- Cytokine Release Syndrome, COVID-19, SARS-CoV-2, Humans, Lung, Endothelial Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.